drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00374 | DB01197 | 1,061 | 1,603 | [
"DDInter1852",
"DDInter292"
] | Treprostinil | Captopril | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Captopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Captopril may be used in the treatment ... | Moderate | 1 | [
[
[
1061,
24,
1603
]
],
[
[
1061,
24,
610
],
[
610,
1,
1603
]
],
[
[
1061,
7,
4893
],
[
4893,
57,
1603
]
],
[
[
1061,
18,
2801
],
[
2801,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Captopril"
]
],
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enalapril"
],
[
... | Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Enalapril and Enalapril (Compound) resembles Captopril (Compound)
Treprostinil (Compound) upregulates S100A13 (Gene) and S100A13 (Gene) is downregulated by Captopril (Compound)
Treprostinil (Compound) downregulates PUF60 (Gene)... |
DB01087 | DB08913 | 1,520 | 1,186 | [
"DDInter1520",
"DDInter1561"
] | Primaquine | Radium Ra 223 dichloride | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Radium Ra 223 Dichloride is a radiopharmaceutical containing the radioisotope radium-223 that emits short range but high linear energy alpha particles. As a cation, radium mimics calicum and binds to hydroxyapatite, which is a bone mineral found in areas of high bone turnover as seen in bone metastases. It was first ap... | Moderate | 1 | [
[
[
1520,
24,
1186
]
],
[
[
1520,
21,
28722
],
[
28722,
60,
1186
]
],
[
[
1520,
24,
1491
],
[
1491,
24,
1186
]
],
[
[
1520,
24,
1619
],
[
... | [
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Radium Ra 223 dichloride"
]
],
[
[
"Primaquine",
"{u} (Compound) causes {v} (Side Effect)",
"Nausea"
],
[
"Nausea",
"{u} (Side Effect)... | Primaquine (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Radium Ra 223 dichloride (Compound)
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken wi... |
DB00041 | DB00690 | 1,648 | 1,216 | [
"DDInter38",
"DDInter762"
] | Aldesleukin | Flurazepam | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This... | A benzodiazepine derivative used mainly as a hypnotic. | Moderate | 1 | [
[
[
1648,
24,
1216
]
],
[
[
1648,
24,
1418
],
[
1418,
1,
1216
]
],
[
[
1648,
24,
481
],
[
481,
40,
1216
]
],
[
[
1648,
24,
104
],
[
104,
... | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurazepam"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estazolam"
],
[
... | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Estazolam and Estazolam (Compound) resembles Flurazepam (Compound)
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Quazepam and Quazepam (Compound) resembles Flurazepam (Compound)
Alde... |
DB04575 | DB06203 | 35 | 1,002 | [
"DDInter1555",
"DDInter51"
] | Quinestrol | Alogliptin | The 3-cyclopentyl ether of ethinyl estradiol. | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25,... | Moderate | 1 | [
[
[
35,
24,
1002
]
],
[
[
35,
24,
1281
],
[
1281,
40,
1002
]
],
[
[
35,
63,
176
],
[
176,
24,
1002
]
],
[
[
35,
40,
566
],
[
566,
24... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
]
],
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Linagliptin"
],
[
... | Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Linagliptin and Linagliptin (Compound) resembles Alogliptin (Compound)
Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interact... |
DB06237 | DB08899 | 438 | 129 | [
"DDInter141",
"DDInter649"
] | Avanafil | Enzalutamide | Avanafil is a phosphodiesterase-5 (PDE5) inhibitor used in the treatment of erectile dysfunction. In comparison with other drugs of the same class, it shows greater selectivity for PDE5 over PDE6 than both [sildenafil] and [vardenafil] but less selectivity than [tadalafil], suggesting a relatively lower risk of visual ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
438,
24,
129
]
],
[
[
438,
6,
8374
],
[
8374,
45,
129
]
],
[
[
438,
21,
29377
],
[
29377,
60,
129
]
],
[
[
438,
24,
1320
],
[
1320,
... | [
[
[
"Avanafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Avanafil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Avanafil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Avanafil (Compound) causes Musculoskeletal pain (Side Effect) and Musculoskeletal pain (Side Effect) is caused by Enzalutamide (Compound)
Avanafil may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00910 | DB12130 | 1,041 | 1,017 | [
"DDInter1394",
"DDInter1094"
] | Paricalcitol | Lorlatinib | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1041,
24,
1017
]
],
[
[
1041,
24,
214
],
[
214,
24,
1017
]
],
[
[
1041,
25,
1196
],
[
1196,
24,
1017
]
],
[
[
1041,
24,
1654
],
[
1654... | [
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Paricalcitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
... | Paricalcitol may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Paricalcitol may lead to a major life threatening interaction when taken with Doxercalciferol and Doxercal... |
DB08865 | DB12095 | 1,593 | 179 | [
"DDInter448",
"DDInter1760"
] | Crizotinib | Telotristat ethyl | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Telotristat ethyl is a prodrug of telotristat that was approved by the FDA in March 2017 as Xermelo. It was previously referred to as telotristat etiprate, the hippurate salt form; however, the FDA recommends the use of the name of the neutral form rather than that of the salt.[A252937, A252942] Currently, telotristat ... | Moderate | 1 | [
[
[
1593,
24,
179
]
],
[
[
1593,
64,
79
],
[
79,
24,
179
]
],
[
[
1593,
63,
310
],
[
310,
24,
179
]
],
[
[
1593,
24,
214
],
[
214,
2... | [
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telotristat ethyl"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sora... | Crizotinib may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telotristat ethyl
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may... |
DB00853 | DB08886 | 1,686 | 637 | [
"DDInter1762",
"DDInter126"
] | Temozolomide | Asparaginase Erwinia chrysanthemi | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alky... | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Moderate | 1 | [
[
[
1686,
24,
637
]
],
[
[
1686,
24,
328
],
[
328,
24,
637
]
],
[
[
1686,
63,
267
],
[
267,
24,
637
]
],
[
[
1686,
24,
1613
],
[
1613,
... | [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"... | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Temozolomide may cause a moderate interaction that could exacerbate diseases wh... |
DB00679 | DB00782 | 684 | 1,123 | [
"DDInter1796",
"DDInter1535"
] | Thioridazine | Propantheline | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazi... | A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking. | Moderate | 1 | [
[
[
684,
24,
1123
]
],
[
[
684,
6,
4304
],
[
4304,
45,
1123
]
],
[
[
684,
18,
1954
],
[
1954,
57,
1123
]
],
[
[
684,
21,
28898
],
[
28898,... | [
[
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propantheline"
]
],
[
[
"Thioridazine",
"{u} (Compound) binds {v} (Gene)",
"CHRM2"
],
[
"CHRM2",
"{u} (Gene) is bound by {v} (Compou... | Thioridazine (Compound) binds CHRM2 (Gene) and CHRM2 (Gene) is bound by Propantheline (Compound)
Thioridazine (Compound) downregulates COG2 (Gene) and COG2 (Gene) is downregulated by Propantheline (Compound)
Thioridazine (Compound) causes Constipation (Side Effect) and Constipation (Side Effect) is caused by Propanthel... |
DB00280 | DB13074 | 494 | 877 | [
"DDInter575",
"DDInter1110"
] | Disopyramide | Macimorelin | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
494,
25,
877
]
],
[
[
494,
23,
112
],
[
112,
23,
877
]
],
[
[
494,
24,
85
],
[
85,
24,
877
]
],
[
[
494,
25,
913
],
[
913,
24,
... | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Disopyramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metr... | Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Atropine and A... |
DB01073 | DB10795 | 1,488 | 221 | [
"DDInter745",
"DDInter1486"
] | Fludarabine | Poliovirus type 1 antigen (formaldehyde inactivated) | Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara. | Poliovirus type 1 antigen is a suspension of poliovirus Type 1 (Mahoney) used in the active immunization of infants (as young as 6 weeks of age), children, and adults for the prevention of poliomyelitis caused by poliovirus Type 1. The vaccine contains purified and inactivated poliovirus type 1 that were grown from a c... | Moderate | 1 | [
[
[
1488,
24,
221
]
],
[
[
1488,
24,
36
],
[
36,
24,
221
]
],
[
[
1488,
64,
581
],
[
581,
24,
221
]
],
[
[
1488,
63,
599
],
[
599,
2... | [
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Poliovirus type 1 antigen (formaldehyde inactivated)"
]
],
[
[
"Fludarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken w... | Fludarabine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Poliovirus type 1 antigen (formaldehyde inactivated)
Fludarabine may lead to a major life threatening interaction when taken w... |
DB00307 | DB00741 | 1,101 | 167 | [
"DDInter202",
"DDInter885"
] | Bexarotene | Hydrocortisone | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone wa... | Moderate | 1 | [
[
[
1101,
24,
167
]
],
[
[
1101,
24,
1220
],
[
1220,
40,
167
]
],
[
[
1101,
25,
303
],
[
303,
40,
167
]
],
[
[
1101,
24,
870
],
[
870,
... | [
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Hydrocortisone (Compound)
Bexarotene may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate (Compound) res... |
DB00252 | DB12500 | 362 | 283 | [
"DDInter1460",
"DDInter714"
] | Phenytoin | Fedratinib | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
362,
25,
283
]
],
[
[
362,
25,
466
],
[
466,
62,
283
]
],
[
[
362,
25,
351
],
[
351,
23,
283
]
],
[
[
362,
25,
1419
],
[
1419,
2... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u}... | Phenytoin may lead to a major life threatening interaction when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Phenytoin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interac... |
DB00434 | DB01452 | 13 | 993 | [
"DDInter459",
"DDInter532"
] | Cyproheptadine | Diamorphine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is ... | Moderate | 1 | [
[
[
13,
24,
993
]
],
[
[
13,
63,
421
],
[
421,
40,
993
]
],
[
[
13,
63,
475
],
[
475,
25,
993
]
],
[
[
13,
24,
770
],
[
770,
24,
... | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diamorphine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydromorphone"
... | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Diamorphine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threate... |
DB00342 | DB01149 | 1,181 | 851 | [
"DDInter1770",
"DDInter1274"
] | Terfenadine | Nefazodone | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Nefazodone hydrochloride (trade name Serzone) is an antidepressant drug marketed by Bristol-Myers Squibb. Its sale was discontinued in 2003 in some countries, due to the small possibility of hepatic (liver) injury. Drug-induced hepatic injuries were associated with an risk of elevated need for a liver transplant, or ev... | Major | 2 | [
[
[
1181,
25,
851
]
],
[
[
1181,
24,
252
],
[
252,
40,
851
]
],
[
[
1181,
24,
1178
],
[
1178,
1,
851
]
],
[
[
1181,
63,
1101
],
[
1101,
... | [
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nefazodone"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxyzine"
],
[
"Hydroxy... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxyzine and Hydroxyzine (Compound) resembles Nefazodone (Compound)
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Nefazodo... |
DB00059 | DB01276 | 1,560 | 123 | [
"DDInter1404",
"DDInter706"
] | Pegaspargase | Exenatide | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagi... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1560,
24,
123
]
],
[
[
1560,
24,
1463
],
[
1463,
23,
123
]
],
[
[
1560,
24,
1072
],
[
1072,
24,
123
]
],
[
[
1560,
24,
984
],
[
984,
... | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[... | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isonia... |
DB00759 | DB00880 | 1,620 | 359 | [
"DDInter1783",
"DDInter360"
] | Tetracycline | Chlorothiazide | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some e... | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812) | Minor | 0 | [
[
[
1620,
23,
359
]
],
[
[
1620,
23,
1577
],
[
1577,
1,
359
]
],
[
[
1620,
62,
1014
],
[
1014,
1,
359
]
],
[
[
1620,
6,
10612
],
[
10612,
... | [
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chlorothiazide"
]
],
[
[
"Tetracycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydroflumethiazide"
... | Tetracycline may cause a minor interaction that can limit clinical effects when taken with Hydroflumethiazide and Hydroflumethiazide (Compound) resembles Chlorothiazide (Compound)
Tetracycline may cause a minor interaction that can limit clinical effects when taken with Benzthiazide and Benzthiazide (Compound) resemble... |
DB00865 | DB09043 | 939 | 135 | [
"DDInter187",
"DDInter36"
] | Benzphetamine | Albiglutide | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
939,
24,
135
]
],
[
[
939,
63,
1647
],
[
1647,
23,
135
]
],
[
[
939,
40,
362
],
[
362,
24,
135
]
],
[
[
939,
63,
176
],
[
176,
2... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acarbose"
],
... | Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose and Acarbose may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Benzphetamine (Compound) resembles Phenytoin (Compound) and Phenytoin may cause a moderate interaction that could ... |
DB00283 | DB10429 | 701 | 200 | [
"DDInter395",
"DDInter282"
] | Clemastine | Candida albicans | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Candida albicans is a fungus which can provoke allergic reactions. Candida albicans is used in allergenic testing. | Moderate | 1 | [
[
[
701,
24,
200
]
],
[
[
701,
24,
662
],
[
662,
24,
200
]
],
[
[
701,
35,
1242
],
[
1242,
24,
200
]
],
[
[
701,
24,
662
],
[
662,
6... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
]
],
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],... | Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Clemastine (Compound) resembles Cetirizine (Compound) and Clemastine may cause a moderate interactio... |
DB00280 | DB09082 | 494 | 659 | [
"DDInter575",
"DDInter1934"
] | Disopyramide | Vilanterol | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug... | Moderate | 1 | [
[
[
494,
24,
659
]
],
[
[
494,
24,
1220
],
[
1220,
23,
659
]
],
[
[
494,
24,
1296
],
[
1296,
63,
659
]
],
[
[
494,
25,
927
],
[
927,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Insulin deglu... |
DB00370 | DB06704 | 1,251 | 247 | [
"DDInter1230",
"DDInter952"
] | Mirtazapine | Iobenguane (I-131) | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Major | 2 | [
[
[
1251,
37,
247
]
],
[
[
1251,
6,
7390
],
[
7390,
45,
247
]
],
[
[
1251,
21,
28787
],
[
28787,
60,
247
]
],
[
[
1251,
24,
820
],
[
820,
... | [
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"SLC6... | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Mirtazapine may lead to a major life threatening interaction when taken with Iobenguane
Mirtazapine (Compound) binds SLC6A2 (Gene) and SLC6A2 (Gene) is bound by Iobenguane (Compound)
Mirtazapine (Compound) causes ... |
DB01218 | DB12130 | 1,493 | 1,017 | [
"DDInter852",
"DDInter1094"
] | Halofantrine | Lorlatinib | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
1493,
24,
1017
]
],
[
[
1493,
25,
1612
],
[
1612,
23,
1017
]
],
[
[
1493,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1493,
25,
786
],
[
786... | [
[
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fostemsavir"
],
[
"Foste... | Halofantrine may lead to a major life threatening interaction when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may ca... |
DB00916 | DB01166 | 112 | 477 | [
"DDInter1202",
"DDInter379"
] | Metronidazole | Cilostazol | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Minor | 0 | [
[
[
112,
23,
477
]
],
[
[
112,
6,
8374
],
[
8374,
45,
477
]
],
[
[
112,
21,
29340
],
[
29340,
60,
477
]
],
[
[
112,
23,
1247
],
[
1247,
... | [
[
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Metronidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Metronidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Metronidazole (Compound) causes Stevens-Johnson syndrome (Side Effect) and Stevens-Johnson syndrome (Side Effect) is caused by Cilostazol (Compound)
Metronidazole may cause a minor interaction that can limit clinical effect... |
DB09046 | DB09389 | 1,094 | 517 | [
"DDInter1201",
"DDInter1315"
] | Metreleptin | Norgestrel | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only the levorotary enantiomer ([levonorgestrel]) is biologically active. | Moderate | 1 | [
[
[
1094,
24,
517
]
],
[
[
1094,
24,
159
],
[
159,
63,
517
]
],
[
[
1094,
63,
1254
],
[
1254,
24,
517
]
],
[
[
1094,
24,
1362
],
[
1362,
... | [
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
]
],
[
[
"Metreleptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel
Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin gluli... |
DB00835 | DB14881 | 100 | 180 | [
"DDInter245",
"DDInter1329"
] | Brompheniramine | Oliceridine | Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria. | Severe acute pain occurs through nociceptive signalling involving both ascending and descending spinal pathways, in which nerve conductance is mediated in part by the action of opioid receptors.[A218041, A218046] Opioid receptors are seven-transmembrane G-protein-coupled receptors (GPCRs), of which the μ-opioid recepto... | Moderate | 1 | [
[
[
100,
24,
180
]
],
[
[
100,
24,
401
],
[
401,
24,
180
]
],
[
[
100,
63,
85
],
[
85,
24,
180
]
],
[
[
100,
1,
28
],
[
28,
24,
... | [
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
]
],
[
[
"Brompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
... | Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine
Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Atropi... |
DB05239 | DB11791 | 866 | 785 | [
"DDInter425",
"DDInter287"
] | Cobimetinib | Capmatinib | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment ... | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
866,
24,
785
]
],
[
[
866,
63,
1324
],
[
1324,
24,
785
]
],
[
[
866,
24,
1320
],
[
1320,
63,
785
]
],
[
[
866,
24,
850
],
[
850,
... | [
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and El... |
DB00802 | DB01041 | 1,322 | 770 | [
"DDInter43",
"DDInter1789"
] | Alfentanil | Thalidomide | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
1322,
24,
770
]
],
[
[
1322,
6,
7524
],
[
7524,
45,
770
]
],
[
[
1322,
21,
28789
],
[
28789,
60,
770
]
],
[
[
1322,
25,
609
],
[
609,
... | [
[
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Alfentanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)"... | Alfentanil (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Thalidomide (Compound)
Alfentanil (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Thalidomide (Compound)
Alfentanil may lead to a major life threatening interaction when taken with Clarithr... |
DB01017 | DB08938 | 1,669 | 1,384 | [
"DDInter1224",
"DDInter1112"
] | Minocycline | Magaldrate | Minocycline was first described in the literacture in 1966. It is a second generation tetracycline antibiotic that is active against gram-negative and gram-positive bacteria. Like other semisynthetic tetracyclines, minocycline has modifications to carbons 7-9 on the D ring to generate higher efficacy than previous tetr... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Moderate | 1 | [
[
[
1669,
24,
1384
]
],
[
[
1669,
63,
1252
],
[
1252,
23,
1384
]
],
[
[
1669,
40,
964
],
[
964,
24,
1384
]
],
[
[
1669,
24,
428
],
[
428,
... | [
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magaldrate"
]
],
[
[
"Minocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Minocycline may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Minocycline (Compound) resembles Doxycycline (Compound) and Doxycycline may cause a moderate interaction that could exa... |
DB00370 | DB00916 | 1,251 | 112 | [
"DDInter1230",
"DDInter1202"
] | Mirtazapine | Metronidazole | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Minor | 0 | [
[
[
1251,
23,
112
]
],
[
[
1251,
6,
3486
],
[
3486,
45,
112
]
],
[
[
1251,
21,
28692
],
[
28692,
60,
112
]
],
[
[
1251,
63,
618
],
[
618,
... | [
[
[
"Mirtazapine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
]
],
[
[
"Mirtazapine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound... | Mirtazapine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Mirtazapine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Metronidazole (Compound)
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00414 | DB06292 | 590 | 549 | [
"DDInter16",
"DDInter474"
] | Acetohexamide | Dapagliflozin | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
590,
24,
549
]
],
[
[
590,
24,
1344
],
[
1344,
40,
549
]
],
[
[
590,
62,
1103
],
[
1103,
23,
549
]
],
[
[
590,
24,
463
],
[
463,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction ... |
DB00771 | DB01246 | 262 | 820 | [
"DDInter397",
"DDInter45"
] | Clidinium | Alimemazine | Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the tr... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
262,
24,
820
]
],
[
[
262,
24,
358
],
[
358,
24,
820
]
],
[
[
262,
24,
104
],
[
104,
40,
820
]
],
[
[
262,
74,
675
],
[
675,
25,... | [
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Clidinium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
],
[
... | Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Clidinium may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and M... |
DB00357 | DB01591 | 1,051 | 667 | [
"DDInter71",
"DDInter1696"
] | Aminoglutethimide | Solifenacin | An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids. It also blocks the conversion of androgens to estrogens. Aminoglutethimide has been used in the treatment of advanced breast and prostate cancer. It was formerly used for its weak anticonvulsant prope... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1051,
24,
667
]
],
[
[
1051,
6,
8374
],
[
8374,
45,
667
]
],
[
[
1051,
21,
28703
],
[
28703,
60,
667
]
],
[
[
1051,
24,
392
],
[
392,
... | [
[
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Aminoglutethimide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {... | Aminoglutethimide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Aminoglutethimide (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Solifenacin (Compound)
Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01001 | DB04868 | 688 | 478 | [
"DDInter1632",
"DDInter1293"
] | Salbutamol | Nilotinib | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formu... | Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to ... | Moderate | 1 | [
[
[
688,
24,
478
]
],
[
[
688,
6,
8374
],
[
8374,
45,
478
]
],
[
[
688,
6,
3576
],
[
3576,
46,
478
]
],
[
[
688,
21,
28963
],
[
28963,
... | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
]
],
[
[
"Salbutamol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Nilotinib (Compound)
Salbutamol (Compound) binds ADRB2 (Gene) and ADRB2 (Gene) is upregulated by Nilotinib (Compound)
Salbutamol (Compound) causes Anxiety (Side Effect) and Anxiety (Side Effect) is caused by Nilotinib (Compound)
Salbutamol may caus... |
DB05273 | DB12332 | 507 | 1,619 | [
"DDInter1638",
"DDInter1626"
] | Samarium (153Sm) lexidronam | Rucaparib | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Major | 2 | [
[
[
507,
25,
1619
]
],
[
[
507,
64,
309
],
[
309,
24,
1619
]
],
[
[
507,
25,
738
],
[
738,
24,
1619
]
],
[
[
507,
63,
563
],
[
563,
... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixabepilone"
],
... | Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Niraparib and Ni... |
DB06717 | DB12010 | 875 | 214 | [
"DDInter778",
"DDInter785"
] | Fosaprepitant | Fostamatinib | Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
875,
24,
214
]
],
[
[
875,
24,
976
],
[
976,
24,
214
]
],
[
[
875,
40,
723
],
[
723,
24,
214
]
],
[
[
875,
64,
866
],
[
866,
24,... | [
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Fosaprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],... | Fosaprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Fosaprepitant (Compound) resembles Aprepitant (Compound) and Aprepitant may cause a moderate interaction ... |
DB00734 | DB00981 | 1,664 | 1,528 | [
"DDInter1605",
"DDInter1462"
] | Risperidone | Physostigmine | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity. | Moderate | 1 | [
[
[
1664,
24,
1528
]
],
[
[
1664,
21,
28751
],
[
28751,
60,
1528
]
],
[
[
1664,
24,
1511
],
[
1511,
63,
1528
]
],
[
[
1664,
24,
543
],
[
5... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Risperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) ... | Risperidone (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Physostigmine (Compound)
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB01095 | DB08904 | 671 | 375 | [
"DDInter769",
"DDInter342"
] | Fluvastatin | Certolizumab pegol | Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to r... | Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent compl... | Moderate | 1 | [
[
[
671,
24,
375
]
],
[
[
671,
24,
1047
],
[
1047,
24,
375
]
],
[
[
671,
24,
1434
],
[
1434,
63,
375
]
],
[
[
671,
63,
10
],
[
10,
2... | [
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
]
],
[
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtan... | Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol
Fluvastatin may cause a moderate interaction that could exacerbate diseases when ... |
DB04855 | DB09080 | 540 | 144 | [
"DDInter602",
"DDInter1331"
] | Dronedarone | Olodaterol | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate contro... | Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, v... | Moderate | 1 | [
[
[
540,
24,
144
]
],
[
[
540,
25,
1011
],
[
1011,
24,
144
]
],
[
[
540,
64,
11
],
[
11,
24,
144
]
],
[
[
540,
63,
1324
],
[
1324,
2... | [
[
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
]
],
[
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolim... | Dronedarone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol
Dronedarone may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate in... |
DB06616 | DB09065 | 594 | 760 | [
"DDInter224",
"DDInter424"
] | Bosutinib | Cobicistat | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
594,
25,
760
]
],
[
[
594,
63,
479
],
[
479,
23,
760
]
],
[
[
594,
24,
1627
],
[
1627,
23,
760
]
],
[
[
594,
64,
1230
],
[
1230,
... | [
[
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
... | Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol... |
DB06081 | DB08896 | 1,046 | 292 | [
"DDInter286",
"DDInter1576"
] | Caplacizumab | Regorafenib | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Major | 2 | [
[
[
1046,
25,
292
]
],
[
[
1046,
24,
643
],
[
643,
24,
292
]
],
[
[
1046,
63,
1560
],
[
1560,
24,
292
]
],
[
[
1046,
24,
41
],
[
41,
... | [
[
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desvenlafaxine"
],
[
"D... | Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Desvenlafaxine and Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Pegaspar... |
DB00980 | DB04837 | 969 | 649 | [
"DDInter1564",
"DDInter407"
] | Ramelteon | Clofedanol | Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse. | Clofedanol is a centrally-acting cough suppressant available in Canada under the trade name Ulone. It is not available in the United States. | Moderate | 1 | [
[
[
969,
24,
649
]
],
[
[
969,
24,
1376
],
[
1376,
24,
649
]
],
[
[
969,
63,
832
],
[
832,
40,
649
]
],
[
[
969,
63,
701
],
[
701,
2... | [
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofedanol"
]
],
[
[
"Ramelteon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diphenhydramine"
],
[... | Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Clofedanol
Ramelteon may cause a moderate interaction that could exacerbate diseases when taken with Tripelennamin... |
DB00906 | DB12267 | 1,567 | 1,476 | [
"DDInter1801",
"DDInter233"
] | Tiagabine | Brigatinib | Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
1567,
24,
1476
]
],
[
[
1567,
63,
629
],
[
629,
24,
1476
]
],
[
[
1567,
24,
478
],
[
478,
24,
1476
]
],
[
[
1567,
24,
1619
],
[
1619,
... | [
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Tiagabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
... | Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Tiagabine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib m... |
DB06704 | DB14444 | 247 | 151 | [
"DDInter952",
"DDInter924"
] | Iobenguane (I-131) | Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated) | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | A seasonally-specific component of the influenza vaccine. The influenza vaccine, also known as the "flu shot", is a vaccine that protects against infection from the influenza viruses. Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immuno... | Moderate | 1 | [
[
[
247,
24,
151
]
],
[
[
247,
7,
6952
],
[
6952,
46,
77
],
[
77,
24,
151
]
],
[
[
247,
18,
7359
],
[
7359,
57,
147
],
[
147,
24,
... | [
[
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)"
]
],
[
[
"Iobenguane",
"{u} (Compound) upregulates {v} (Gene)",
"MC... | Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Iobenguane (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Idarubicin (Compound) and Idarubicin may cause a moderate i... |
DB00792 | DB01238 | 832 | 673 | [
"DDInter1878",
"DDInter118"
] | Tripelennamine | Aripiprazole | A histamine H1 antagonist with low sedative action but frequent gastrointestinal irritation. It is used to treat asthma; HAY fever; urticaria; and rhinitis; and also in veterinary applications. Tripelennamine is administered by various routes, including topically. | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
832,
24,
673
]
],
[
[
832,
24,
851
],
[
851,
1,
673
]
],
[
[
832,
63,
827
],
[
827,
40,
673
]
],
[
[
832,
6,
12523
],
[
12523,
4... | [
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Tripelennamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
]... | Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Tripelennamine may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (... |
DB00549 | DB00701 | 522 | 1,091 | [
"DDInter1955",
"DDInter90"
] | Zafirlukast | Amprenavir | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Amprenavir is a protease inhibitor used to treat HIV infection. | Minor | 0 | [
[
[
522,
23,
1091
]
],
[
[
522,
6,
10215
],
[
10215,
45,
1091
]
],
[
[
522,
21,
28996
],
[
28996,
60,
1091
]
],
[
[
522,
23,
222
],
[
222,... | [
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amprenavir"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)... | Zafirlukast (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Amprenavir (Compound)
Zafirlukast (Compound) causes Musculoskeletal discomfort (Side Effect) and Musculoskeletal discomfort (Side Effect) is caused by Amprenavir (Compound)
Zafirlukast may cause a minor interaction that can limit clinical effect... |
DB00108 | DB10583 | 1,066 | 949 | [
"DDInter1268",
"DDInter415"
] | Natalizumab | Clostridium tetani toxoid antigen (formaldehyde inactivated) | Natalizumab is a recombinant humanized IgG4κ monoclonal antibody that binds to α4-integrin. While natalizumab was originally approved by the FDA to treat multiple sclerosis in 2004, it was withdrawn from the market following multiple reports of fatal progressive multifocal leukoencephalopathy (PML). In 2006, the FDA re... | Clostridium tetani toxoid antigen (formaldehyde inactivated) is a vaccine for intramuscular injection. It is used for active immunization of children 7 years of age or older, and adults, for prevention of tetanus. The toxoid in the Clostridium tetani culture is grown and detoxified followed by purification via ammonium... | Moderate | 1 | [
[
[
1066,
24,
949
]
],
[
[
1066,
64,
550
],
[
550,
24,
949
]
],
[
[
1066,
25,
589
],
[
589,
24,
949
]
],
[
[
1066,
25,
1093
],
[
1093,
... | [
[
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
]
],
[
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}... | Natalizumab may lead to a major life threatening interaction when taken with Trastuzumab and Trastuzumab may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated)
Natalizumab may lead to a major life threatening interaction when taken wi... |
DB00196 | DB09118 | 600 | 1,580 | [
"DDInter743",
"DDInter1711"
] | Fluconazole | Stiripentol | Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole ... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
600,
24,
1580
]
],
[
[
600,
23,
466
],
[
466,
62,
1580
]
],
[
[
600,
24,
1409
],
[
1409,
24,
1580
]
],
[
[
600,
24,
283
],
[
283,
... | [
[
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Fluconazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[... | Fluconazole may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol
Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixa... |
DB00209 | DB00844 | 352 | 314 | [
"DDInter1886",
"DDInter1257"
] | Trospium | Nalbuphine | Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevu... | A narcotic used as a pain medication. It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors. Nalbuphine is the only opioid analgesic that is not a controlled substance in the United States. | Moderate | 1 | [
[
[
352,
24,
314
]
],
[
[
352,
24,
828
],
[
828,
40,
314
]
],
[
[
352,
24,
421
],
[
421,
1,
314
]
],
[
[
352,
24,
475
],
[
475,
25,
... | [
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
]
],
[
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"... | Trospium may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone (Compound) resembles Nalbuphine (Compound)
Trospium may cause a moderate interaction that could exacerbate diseases when taken with Hydromorphone and Hydromorphone (Compound) resembles Nalbuphine (Compound)
... |
DB11793 | DB11986 | 738 | 484 | [
"DDInter1297",
"DDInter648"
] | Niraparib | Entrectinib | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
738,
24,
484
]
],
[
[
738,
24,
466
],
[
466,
62,
484
]
],
[
[
738,
63,
998
],
[
998,
24,
484
]
],
[
[
738,
24,
1320
],
[
1320,
2... | [
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
... | Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Phenylbutazone and P... |
DB01242 | DB12141 | 1,237 | 971 | [
"DDInter410",
"DDInter817"
] | Clomipramine | Gilteritinib | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1237,
24,
971
]
],
[
[
1237,
62,
112
],
[
112,
23,
971
]
],
[
[
1237,
63,
485
],
[
485,
24,
971
]
],
[
[
1237,
24,
823
],
[
823,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Clomipramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Clomipramine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine a... |
DB01211 | DB09079 | 609 | 1,496 | [
"DDInter393",
"DDInter1296"
] | Clarithromycin | Nintedanib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Nintedanib is a small molecule kinase inhibitor used in the treatment of pulmonary fibrosis, systemic sclerosis-associated interstitial lung disease, and non-small cell lung cancer (NSCLC).[L8453,L8459] It was first approved for use in the United States in 2014. Within the spectrum of idiopathic pulmonary fibrosis trea... | Moderate | 1 | [
[
[
609,
24,
1496
]
],
[
[
609,
64,
33
],
[
33,
24,
1496
]
],
[
[
609,
24,
74
],
[
74,
24,
1496
]
],
[
[
609,
24,
1412
],
[
1412,
63... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nintedanib"
]
],
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Am... | Clarithromycin may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Boceprevir and Boceprevir ma... |
DB09030 | DB11901 | 840 | 913 | [
"DDInter1945",
"DDInter107"
] | Vorapaxar | Apalutamide | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Major | 2 | [
[
[
840,
25,
913
]
],
[
[
840,
64,
279
],
[
279,
24,
913
]
],
[
[
840,
63,
1237
],
[
1237,
24,
913
]
],
[
[
840,
24,
1496
],
[
1496,
... | [
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Vorapaxar",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
],
[
"Anisindione",
"{u} ... | Vorapaxar may lead to a major life threatening interaction when taken with Anisindione and Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Vorapaxar may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may c... |
DB00197 | DB08881 | 1,324 | 868 | [
"DDInter1881",
"DDInter1925"
] | Troglitazone | Vemurafenib | Troglitazone was withdrawn in 2000 due to risk of hepatotoxicity. It was superseded by [pioglitazone] and [rosiglitazone]. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann L... | Moderate | 1 | [
[
[
1324,
24,
868
]
],
[
[
1324,
23,
608
],
[
608,
23,
868
]
],
[
[
1324,
23,
271
],
[
271,
62,
868
]
],
[
[
1324,
24,
479
],
[
479,
... | [
[
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Troglitazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
... | Troglitazone may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Troglitazone may cause a minor interaction that can limit clinical effects when taken with Mirabegron and Mirabegro... |
DB00193 | DB00747 | 534 | 1,442 | [
"DDInter1841",
"DDInter1647"
] | Tramadol | Scopolamine | Tramadol is a centrally acting synthetic opioid analgesic and SNRI (serotonin/norepinephrine reuptake-inhibitor) that is structurally related to [codeine] and [morphine]. Due to its good tolerability profile and multimodal mechanism of action, tramadol is generally considered a lower-risk opioid option for the treatmen... | Scopolamine is a tropane alkaloid isolated from members of the _Solanaceae_ family of plants, similar to [atropine] and [hyoscyamine], all of which structurally mimic the natural neurotransmitter [acetylcholine].[A228423, A228763] Scopolamine was first synthesized in 1959, but to date, synthesis remains less efficient ... | Moderate | 1 | [
[
[
534,
24,
1442
]
],
[
[
534,
24,
19
],
[
19,
24,
1442
]
],
[
[
534,
6,
2720
],
[
2720,
45,
1442
]
],
[
[
534,
21,
28766
],
[
28766,
... | [
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Scopolamine"
]
],
[
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hyoscyamine"
],
[
... | Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken with Scopolamine
Tramadol (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Scopolamine (Compound)
Tramadol (Compound) ... |
DB00013 | DB11312 | 1,255 | 298 | [
"DDInter1905",
"DDInter1542"
] | Urokinase | Protein C | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the e... | Moderate | 1 | [
[
[
1255,
24,
298
]
],
[
[
1255,
25,
500
],
[
500,
24,
298
]
],
[
[
1255,
64,
942
],
[
942,
24,
298
]
],
[
[
1255,
25,
1421
],
[
1421,
... | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
... | Urokinase may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Urokinase may lead to a major life threatening interaction when taken with Bivalirudin and Bivalirudin may cause a moderate inter... |
DB00820 | DB12130 | 402 | 1,017 | [
"DDInter1736",
"DDInter1094"
] | Tadalafil | Lorlatinib | Tadalafil is a selective phosphodiesterase-5 inhibitor that is used in the treatment of erectile dysfunction (ED), pulmonary arterial hypertension (PAH), and benign prostatic hypertrophy.[L39100, L39105] It was first approved in 2003 by the FDA for use in ED and later in 2009 for PAH. In contrast to other PDE5 inhibito... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Moderate | 1 | [
[
[
402,
24,
1017
]
],
[
[
402,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
402,
24,
549
],
[
549,
24,
1017
]
],
[
[
402,
24,
159
],
[
159,
... | [
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Tadalafil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
... | Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Tadalafil may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagli... |
DB00850 | DB06282 | 1,630 | 516 | [
"DDInter1432",
"DDInter1053"
] | Perphenazine | Levocetirizine | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
1630,
24,
516
]
],
[
[
1630,
63,
701
],
[
701,
24,
516
]
],
[
[
1630,
1,
1178
],
[
1178,
24,
516
]
],
[
[
1630,
24,
407
],
[
407,
... | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
... | Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine
Perphenazine (Compound) resembles Trifluoperazine (Compound) and Trifluoperazine may cause a moderate inte... |
DB11126 | DB11943 | 900 | 255 | [
"DDInter276",
"DDInter495"
] | Calcium gluconate | Delafloxacin | Calcium gluconate is used as mineral supplement and medication when there is insufficient calcium in the diet. Supplementation may be done to treat or prevent osteoporosis or rickets, consequences of hypocalcemia. It can also be taken by mouth but is not recommended by injection into a muscle. Calcium Gluconate Injecti... | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in t... | Moderate | 1 | [
[
[
900,
24,
255
]
],
[
[
900,
63,
729
],
[
729,
23,
1283
],
[
1283,
24,
255
]
],
[
[
900,
63,
945
],
[
945,
62,
1686
],
[
1686,
23,
... | [
[
[
"Calcium gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delafloxacin"
]
],
[
[
"Calcium gluconate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Penbutolol"... | Calcium gluconate may cause a moderate interaction that could exacerbate diseases when taken with Penbutolol and Penbutolol may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with De... |
DB00794 | DB00910 | 759 | 1,041 | [
"DDInter1521",
"DDInter1394"
] | Primidone | Paricalcitol | Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954. | Paricalcitol is a synthetic vitamin D analog. Paricalcitol has been used to reduce parathyroid hormone levels. Paricalcitol is indicated for the prevention and treatment of secondary hyperparathyroidism associated with chronic renal failure. | Moderate | 1 | [
[
[
759,
24,
1041
]
],
[
[
759,
63,
386
],
[
386,
25,
1041
]
],
[
[
759,
24,
1098
],
[
1098,
64,
1041
]
],
[
[
759,
6,
8374
],
[
8374,
... | [
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paricalcitol"
]
],
[
[
"Primidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cholecalciferol"
],
... | Primidone may cause a moderate interaction that could exacerbate diseases when taken with Cholecalciferol and Cholecalciferol may lead to a major life threatening interaction when taken with Paricalcitol
Primidone may cause a moderate interaction that could exacerbate diseases when taken with Dihydrotachysterol and Dih... |
DB06186 | DB12240 | 1,439 | 110 | [
"DDInter969",
"DDInter1485"
] | Ipilimumab | Polatuzumab vedotin | Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes.[A35065,A35080,L12126] Ipilimumab was developed by Bristol-Myers Squibb and Medarex. Ipilimumab was granted FDA approva... | Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable link... | Moderate | 1 | [
[
[
1439,
24,
110
]
],
[
[
1439,
63,
467
],
[
467,
24,
110
]
],
[
[
1439,
24,
980
],
[
980,
24,
110
]
],
[
[
1439,
24,
148
],
[
148,
... | [
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polatuzumab vedotin"
]
],
[
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Simvastatin"
]... | Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Polatuzumab vedotin
Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Tocilizuma... |
DB00398 | DB00640 | 79 | 1,585 | [
"DDInter1702",
"DDInter31"
] | Sorafenib | Adenosine | Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular ca... | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Moderate | 1 | [
[
[
79,
24,
1585
]
],
[
[
79,
24,
372
],
[
372,
1,
1585
]
],
[
[
79,
18,
5416
],
[
5416,
57,
1585
]
],
[
[
79,
21,
28890
],
[
28890,
... | [
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Adenosine"
]
],
[
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofarabine"
],
[
... | Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Clofarabine and Clofarabine (Compound) resembles Adenosine (Compound)
Sorafenib (Compound) downregulates KIF14 (Gene) and KIF14 (Gene) is downregulated by Adenosine (Compound)
Sorafenib (Compound) causes Myocardial infarction (Sid... |
DB00586 | DB01432 | 1,512 | 857 | [
"DDInter537",
"DDInter368"
] | Diclofenac | Cholestyramine | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Cholestyramine or colestyramine is a bile acid sequestrant. Bile acid sequestrants are polymeric compounds which serve as ion exchange resins. Cholestyramine resin is quite hydrophilic, but insoluble in water. | Minor | 0 | [
[
[
1512,
23,
857
]
],
[
[
1512,
24,
1479
],
[
1479,
23,
857
]
],
[
[
1512,
63,
91
],
[
91,
24,
857
]
],
[
[
1512,
24,
1411
],
[
1411,
... | [
[
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cholestyramine"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Cholestyramine
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00637 | DB00983 | 1,557 | 480 | [
"DDInter128",
"DDInter776"
] | Astemizole | Formoterol | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
1557,
24,
480
]
],
[
[
1557,
24,
1148
],
[
1148,
63,
480
]
],
[
[
1557,
6,
12523
],
[
12523,
45,
480
]
],
[
[
1557,
18,
10375
],
[
103... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
... | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Astemizole (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Formoterol (Compound)
Astemizole (Co... |
DB01005 | DB04865 | 995 | 4 | [
"DDInter894",
"DDInter1335"
] | Hydroxyurea | Omacetaxine mepesuccinate | Hydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults. Although clinical evidence on the efficacy of hydroxyurea in certain conditions exists, h... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
995,
24,
4
]
],
[
[
995,
25,
770
],
[
770,
24,
4
]
],
[
[
995,
24,
496
],
[
496,
63,
4
]
],
[
[
995,
63,
66
],
[
66,
24,
4... | [
[
[
"Hydroxyurea",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Hydroxyurea",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[... | Hydroxyurea may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate
Hydroxyurea may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vacci... |
DB00189 | DB06691 | 459 | 849 | [
"DDInter691",
"DDInter1155"
] | Ethchlorvynol | Mepyramine | Ethchlorvynol is a sedative and hypnotic drug. It has been used to treat insomnia, but has been largely superseded and is only offered where an intolerance or allergy to other drugs exists. | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Moderate | 1 | [
[
[
459,
24,
849
]
],
[
[
459,
24,
1594
],
[
1594,
24,
849
]
],
[
[
459,
63,
1648
],
[
1648,
24,
849
]
],
[
[
459,
24,
407
],
[
407,
... | [
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
]
],
[
[
"Ethchlorvynol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
... | Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine
Ethchlorvynol may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and... |
DB00206 | DB00687 | 1,245 | 870 | [
"DDInter1582",
"DDInter747"
] | Reserpine | Fludrocortisone | An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a rese... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1245,
24,
870
]
],
[
[
1245,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1245,
21,
28977
],
[
28977,
60,
870
]
],
[
[
1245,
24,
1148
],
[
114... | [
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Reserpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Reserpine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Reserpine (Compound) causes Vascular purpura (Side Effect) and Vascular purpura (Side Effect) is caused by Fludrocortisone (Compound)
Reserpine may ca... |
DB00703 | DB00816 | 997 | 1,674 | [
"DDInter1167",
"DDInter1346"
] | Methazolamide | Orciprenaline | A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma. | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
997,
24,
1674
]
],
[
[
997,
21,
29305
],
[
29305,
60,
1674
]
],
[
[
997,
63,
251
],
[
251,
23,
1674
]
],
[
[
997,
24,
891
],
[
891,
... | [
[
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Methazolamide",
"{u} (Compound) causes {v} (Side Effect)",
"Dysgeusia"
],
[
"Dysgeusia",
"{u} (Side Effect... | Methazolamide (Compound) causes Dysgeusia (Side Effect) and Dysgeusia (Side Effect) is caused by Orciprenaline (Compound)
Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone may cause a minor interaction that can limit clinical effects when taken... |
DB00556 | DB08865 | 1,262 | 1,593 | [
"DDInter1429",
"DDInter448"
] | Perflutren | Crizotinib | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1262,
25,
1593
]
],
[
[
1262,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
1262,
24,
286
],
[
286,
63,
1593
]
],
[
[
1262,
24,
455
],
[
455... | [
[
[
"Perflutren",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Perflutren",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound... | Perflutren (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when take... |
DB00692 | DB04946 | 274 | 924 | [
"DDInter1448",
"DDInter907"
] | Phentolamine | Iloperidone | Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation. While initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral doses of phentolamine.[... | Iloperidone is an atypical antipsychotic for the treatment of schizophrenia symptoms. Hoechst Marion Roussel Inc. researched the drug until May 1996. In June 1997 they gave the research rights to Titan Pharmaceuticals, who gave the worldwide development, manufacturing, and marketing rights to Novartis in August 1998. O... | Moderate | 1 | [
[
[
274,
24,
924
]
],
[
[
274,
24,
1664
],
[
1664,
1,
924
]
],
[
[
274,
24,
519
],
[
519,
40,
924
]
],
[
[
274,
6,
11204
],
[
11204,
... | [
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloperidone"
]
],
[
[
"Phentolamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Risperidone"
],
... | Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risperidone (Compound) resembles Iloperidone (Compound)
Phentolamine may cause a moderate interaction that could exacerbate diseases when taken with Paliperidone and Paliperidone (Compound) resembles Iloperidone... |
DB00783 | DB00916 | 1,438 | 112 | [
"DDInter679",
"DDInter1202"
] | Estradiol | Metronidazole | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis and giardiasis, and amebiasis which are parasitic infections.[A181036,A181039] Metronidazole has been used as an antibiotic for several ... | Moderate | 1 | [
[
[
1438,
24,
112
]
],
[
[
1438,
24,
458
],
[
458,
40,
112
]
],
[
[
1438,
6,
3486
],
[
3486,
45,
112
]
],
[
[
1438,
21,
29612
],
[
29612,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole (Compound) resembles Metronidazole (Compound)
Estradiol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Metronidazole (Compound)
Estradiol (Compound) causes Loss of libido (Side Effect) and L... |
DB01169 | DB09263 | 57 | 1,436 | [
"DDInter120",
"DDInter1399"
] | Arsenic trioxide | Patiromer | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Major | 2 | [
[
[
57,
25,
1436
]
],
[
[
57,
64,
870
],
[
870,
24,
1436
]
],
[
[
57,
24,
603
],
[
603,
63,
1436
]
],
[
[
57,
24,
286
],
[
286,
25,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Patiromer"
]
],
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocor... | Arsenic trioxide may lead to a major life threatening interaction when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citra... |
DB00682 | DB06590 | 126 | 1,682 | [
"DDInter1951",
"DDInter329"
] | Warfarin | Ceftaroline fosamil | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Ceftaroline fosamil is a cephalosporin antibacterial indicated for the treatment of the following infections caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections. Community-acquired bacterial pneumonia. | Moderate | 1 | [
[
[
126,
24,
1682
]
],
[
[
126,
24,
1462
],
[
1462,
1,
1682
]
],
[
[
126,
63,
149
],
[
149,
40,
1682
]
],
[
[
126,
63,
778
],
[
778,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ceftaroline fosamil"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefditoren"
],
... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefditoren and Cefditoren (Compound) resembles Ceftaroline fosamil (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Ceftazidime and Ceftazidime (Compound) resembles Ceftaroline fos... |
DB00694 | DB01238 | 51 | 673 | [
"DDInter485",
"DDInter118"
] | Daunorubicin | Aripiprazole | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects thr... | Moderate | 1 | [
[
[
51,
24,
673
]
],
[
[
51,
24,
851
],
[
851,
1,
673
]
],
[
[
51,
63,
827
],
[
827,
40,
673
]
],
[
[
51,
6,
7524
],
[
7524,
45,
... | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nefazodone"
],
... | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Nefazodone and Nefazodone (Compound) resembles Aripiprazole (Compound)
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Trazodone and Trazodone (Compound) resembles Aripiprazole (Comp... |
DB01045 | DB01067 | 463 | 959 | [
"DDInter1590",
"DDInter826"
] | Rifampicin | Glipizide | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation ... | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Moderate | 1 | [
[
[
463,
24,
959
]
],
[
[
463,
63,
245
],
[
245,
40,
959
]
],
[
[
463,
24,
1411
],
[
1411,
1,
959
]
],
[
[
463,
6,
8374
],
[
8374,
4... | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
... | Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Glipizide (Compound)
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide (Compound) resembles Glipizide (Compound... |
DB00207 | DB11967 | 1,570 | 710 | [
"DDInter157",
"DDInter210"
] | Azithromycin | Binimetinib | Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually tra... | Binimetinib, also known as _Mektovi_, is a potent and selective oral mitogen-activated protein kinase 1/2 (MEK 1/2) inhibitor which is combined with [Encorafenib].[A34275,L3335] On June 27, 2018, the Food and Drug Administration approved the combination of [Encorafenib] and binimetinib (BRAFTOVI and MEKTOVI, from Array... | Moderate | 1 | [
[
[
1570,
24,
710
]
],
[
[
1570,
25,
1593
],
[
1593,
24,
710
]
],
[
[
1570,
24,
1557
],
[
1557,
24,
710
]
],
[
[
1570,
24,
1619
],
[
1619,... | [
[
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
]
],
[
[
"Azithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizo... | Azithromycin may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Astemizole and Astemizole may c... |
DB00603 | DB01232 | 303 | 1,327 | [
"DDInter1137",
"DDInter1640"
] | Medroxyprogesterone acetate | Saquinavir | Medroxyprogesterone acetate (MPA) is a [progesterone] derivative that is more resistant to metabolism for improved pharmacokinetic properties. MPA can be use to treat secondary amenorrhea, endometrial hyperplasia, abnormal uterine bleeding, osteoporosis, vasomotor symptoms in menopause, vulvar and vaginal atrophy, prev... | Saquinavir is an HIV-1 protease inhibitor used in combination with [ritonavir] and other antiretrovirals for the treatment of human immunodeficiency virus-1 (HIV-1) infection. In 1995 it became the first protease inhibitor approved by the FDA, followed shortly by ritonavir in 1996, and remains in clinical use today due... | Moderate | 1 | [
[
[
303,
24,
1327
]
],
[
[
303,
63,
798
],
[
798,
40,
1327
]
],
[
[
303,
24,
915
],
[
915,
40,
1327
]
],
[
[
303,
62,
215
],
[
215,
... | [
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
]
],
[
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Nelfinavir and Nelfinavir (Compound) resembles Saquinavir (Compound)
Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir (Compound... |
DB00497 | DB01156 | 828 | 593 | [
"DDInter1366",
"DDInter252"
] | Oxycodone | Bupropion | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The f... | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inh... | Major | 2 | [
[
[
828,
25,
593
]
],
[
[
828,
6,
8374
],
[
8374,
45,
593
]
],
[
[
828,
21,
29491
],
[
29491,
60,
593
]
],
[
[
828,
24,
256
],
[
256,
... | [
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
]
],
[
[
"Oxycodone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Bupropion"... | Oxycodone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bupropion (Compound)
Oxycodone (Compound) causes Dental caries (Side Effect) and Dental caries (Side Effect) is caused by Bupropion (Compound)
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Prasugrel and Pr... |
DB01234 | DB06697 | 1,220 | 436 | [
"DDInter513",
"DDInter121"
] | Dexamethasone | Artemether | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Artemether is an antimalarial agent used to treat acute uncomplicated malaria. It is administered in combination with lumefantrine for improved efficacy. This combination therapy exerts its effects against the erythrocytic stages of <i>Plasmodium spp.</i> and may be used to treat infections caused by <i>P. falciparum</... | Moderate | 1 | [
[
[
1220,
24,
436
]
],
[
[
1220,
6,
12523
],
[
12523,
45,
436
]
],
[
[
1220,
25,
283
],
[
283,
63,
436
]
],
[
[
1220,
24,
1040
],
[
1040,
... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Artemether"
]
],
[
[
"Dexamethasone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compo... | Dexamethasone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Artemether (Compound)
Dexamethasone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Artemether
Dexamethasone may cause a m... |
DB14004 | DB15091 | 398 | 676 | [
"DDInter1806",
"DDInter1901"
] | Tildrakizumab | Upadacitinib | Tildrakizumab is a high-affinity, humanized, IgG1 κ antibody targeting interleukin 23 p19 that shows promise in the evolution of treatment strategy in chronic plaque psoriasis. The Food and Drug Administration (FDA) approved ILUMYA (tildrakizumab-asmn) for the treatment of adults with moderate-to-severe plaque psoriasi... | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Major | 2 | [
[
[
398,
25,
676
]
],
[
[
398,
62,
1193
],
[
1193,
23,
676
]
],
[
[
398,
63,
1430
],
[
1430,
24,
676
]
],
[
[
398,
24,
1129
],
[
1129,
... | [
[
[
"Tildrakizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
]
],
[
[
"Tildrakizumab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"... | Tildrakizumab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Upadacitinib
Tildrakizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleuce... |
DB00585 | DB00586 | 1,127 | 1,512 | [
"DDInter1309",
"DDInter537"
] | Nizatidine | Diclofenac | A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers. | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Minor | 0 | [
[
[
1127,
23,
1512
]
],
[
[
1127,
7,
7720
],
[
7720,
45,
1512
]
],
[
[
1127,
6,
4973
],
[
4973,
45,
1512
]
],
[
[
1127,
18,
2801
],
[
2801... | [
[
[
"Nizatidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
]
],
[
[
"Nizatidine",
"{u} (Compound) upregulates {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)... | Nizatidine (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Diclofenac (Compound)
Nizatidine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Diclofenac (Compound)
Nizatidine (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Diclofenac (Compound)
Nizatidine (Compound) ... |
DB00314 | DB00959 | 894 | 1,486 | [
"DDInter288",
"DDInter1191"
] | Capreomycin | Methylprednisolone | Cyclic peptide antibiotic similar to viomycin. It is produced by Streptomyces capreolus. | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
894,
24,
1486
]
],
[
[
894,
24,
175
],
[
175,
40,
1486
]
],
[
[
894,
24,
167
],
[
167,
1,
1486
]
],
[
[
894,
21,
28748
],
[
28748,
... | [
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
... | Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resemble... |
DB00662 | DB00780 | 717 | 551 | [
"DDInter1873",
"DDInter1440"
] | Trimethobenzamide | Phenelzine | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against e... | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Moderate | 1 | [
[
[
717,
24,
551
]
],
[
[
717,
24,
94
],
[
94,
40,
551
]
],
[
[
717,
21,
28762
],
[
28762,
60,
551
]
],
[
[
717,
24,
537
],
[
537,
6... | [
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenelzine"
]
],
[
[
"Trimethobenzamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenacemide"
... | Trimethobenzamide may cause a moderate interaction that could exacerbate diseases when taken with Phenacemide and Phenacemide (Compound) resembles Phenelzine (Compound)
Trimethobenzamide (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Phenelzine (Compound)
Trimethobenzamide may cause a ... |
DB00738 | DB11837 | 485 | 1,297 | [
"DDInter1420",
"DDInter1351"
] | Pentamidine | Osilodrostat | Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of pneumocystis pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects. | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Moderate | 1 | [
[
[
485,
24,
1297
]
],
[
[
485,
23,
112
],
[
112,
23,
1297
]
],
[
[
485,
24,
623
],
[
623,
24,
1297
]
],
[
[
485,
63,
1555
],
[
1555,
... | [
[
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
]
],
[
[
"Pentamidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Pentamidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and ... |
DB01069 | DB01563 | 401 | 680 | [
"DDInter1533",
"DDInter349"
] | Promethazine | Chloral hydrate | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | A hypnotic and sedative used in the treatment of insomnia. The safety margin is too narrow for chloral hydrate to be used as a general anesthetic in humans, but it is commonly used for that purpose in animal experiments. It is no longer considered useful as an anti-anxiety medication. | Moderate | 1 | [
[
[
401,
24,
680
]
],
[
[
401,
24,
272
],
[
272,
24,
680
]
],
[
[
401,
63,
1614
],
[
1614,
24,
680
]
],
[
[
401,
25,
593
],
[
593,
2... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloral hydrate"
]
],
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
... | Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Chloral hydrate
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB00005 | DB15762 | 1,057 | 725 | [
"DDInter687",
"DDInter1644"
] | Etanercept | Satralizumab | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of ... | Satralizumab is a recombinant humanized monoclonal antibody targeted against human interleukin-6 (IL-6) receptors, similar to [tocilizumab], which is produced in Chinese hamster ovary cells and based on an IgG2 framework. Satralizumab is used in the treatment of neuromyelitis optica spectrum disorder (NMOSD), a rare au... | Major | 2 | [
[
[
1057,
25,
725
]
],
[
[
1057,
23,
1193
],
[
1193,
23,
725
]
],
[
[
1057,
25,
1362
],
[
1362,
24,
725
]
],
[
[
1057,
24,
303
],
[
303,
... | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Satralizumab"
]
],
[
[
"Etanercept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc g... | Etanercept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Satralizumab
Etanercept may lead to a major life threatening interaction when taken with Olaparib and Olaparib may caus... |
DB00661 | DB01222 | 122 | 617 | [
"DDInter1928",
"DDInter246"
] | Verapamil | Budesonide | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Budesonide is a glucocorticoid that is a mix of the 22R and 22S epimer used to treat inflammatory conditions of the lungs and intestines such as asthma, COPD, Crohn's disease, and ulcerative colitis.[A188529,A188532] Budesonide was granted FDA approval on 14 February 1994. It is also available in a combination product ... | Moderate | 1 | [
[
[
122,
24,
617
]
],
[
[
122,
63,
251
],
[
251,
1,
617
]
],
[
[
122,
24,
1220
],
[
1220,
1,
617
]
],
[
[
122,
6,
8374
],
[
8374,
45... | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Budesonide"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betamethasone"
],
[
... | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Budesonide (Compound)
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Budesonide (... |
DB00783 | DB09043 | 1,438 | 135 | [
"DDInter679",
"DDInter36"
] | Estradiol | Albiglutide | Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vag... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1438,
24,
135
]
],
[
[
1438,
63,
126
],
[
126,
23,
135
]
],
[
[
1438,
63,
870
],
[
870,
24,
135
]
],
[
[
1438,
24,
629
],
[
629,
... | [
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
... | Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludroco... |
DB11730 | DB11986 | 351 | 484 | [
"DDInter1588",
"DDInter648"
] | Ribociclib | Entrectinib | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Major | 2 | [
[
[
351,
25,
484
]
],
[
[
351,
62,
1247
],
[
1247,
23,
484
]
],
[
[
351,
23,
466
],
[
466,
62,
484
]
],
[
[
351,
64,
1135
],
[
1135,
... | [
[
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfa... | Ribociclib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Ribociclib may cause a minor interaction that can limit clinical effects when taken with Darolutamide a... |
DB06626 | DB09122 | 263 | 1,613 | [
"DDInter147",
"DDInter1409"
] | Axitinib | Peginterferon beta-1a | Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times hi... | Multiple Sclerosis (MS) is a chronic and inflammatory autoimmune disease of the central nervous system, disrupting communication between the brain and other parts of the body. Most patients diagnosed with this illness experience their initial disease symptoms between the age of 20 to 40, often the most productive years... | Moderate | 1 | [
[
[
263,
24,
1613
]
],
[
[
263,
24,
1627
],
[
1627,
24,
1613
]
],
[
[
263,
64,
152
],
[
152,
24,
1613
]
],
[
[
263,
63,
600
],
[
600,
... | [
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon beta-1a"
]
],
[
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
... | Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon beta-1a
Axitinib may lead to a major life threatening interaction when taken with Bosentan and Bosentan may c... |
DB08868 | DB11730 | 1,011 | 351 | [
"DDInter737",
"DDInter1588"
] | Fingolimod | Ribociclib | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
1011,
25,
351
]
],
[
[
1011,
62,
1247
],
[
1247,
23,
351
]
],
[
[
1011,
24,
1627
],
[
1627,
23,
351
]
],
[
[
1011,
63,
479
],
[
479,
... | [
[
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Fingolimod",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfam... | Fingolimod may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol a... |
DB00446 | DB00758 | 597 | 1,347 | [
"DDInter351",
"DDInter413"
] | Chloramphenicol | Clopidogrel | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recen... | Moderate | 1 | [
[
[
597,
24,
1347
]
],
[
[
597,
6,
3486
],
[
3486,
45,
1347
]
],
[
[
597,
7,
5182
],
[
5182,
45,
1347
]
],
[
[
597,
7,
2903
],
[
2903,
... | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
]
],
[
[
"Chloramphenicol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (... | Chloramphenicol (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Clopidogrel (Compound)
Chloramphenicol (Compound) upregulates CES1 (Gene) and CES1 (Gene) is bound by Clopidogrel (Compound)
Chloramphenicol (Compound) upregulates MMP1 (Gene) and MMP1 (Gene) is upregulated by Clopidogrel (Compound)
Chloramphe... |
DB01087 | DB09083 | 1,520 | 880 | [
"DDInter1520",
"DDInter996"
] | Primaquine | Ivabradine | An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Ad... | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus r... | Major | 2 | [
[
[
1520,
25,
880
]
],
[
[
1520,
63,
480
],
[
480,
24,
880
]
],
[
[
1520,
24,
659
],
[
659,
24,
880
]
],
[
[
1520,
25,
1011
],
[
1011,
... | [
[
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
]
],
[
[
"Primaquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol... | Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ivabradine
Primaquine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilant... |
DB00376 | DB01114 | 1,105 | 272 | [
"DDInter1870",
"DDInter362"
] | Trihexyphenidyl | Chlorpheniramine | Trihexyphenidyl is a centrally acting muscarinic antagonist used for treatment of parkinsonism and drug-induced extrapyramidal disorders.[L31773,L31778] Its discovery was published in 1949 in a study looking for drugs with antispasmodic activity. Trihexyphenidyl is rarely used in the treatment of parkinsonism, and is n... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1105,
24,
272
]
],
[
[
1105,
1,
11268
],
[
11268,
1,
272
]
],
[
[
1105,
24,
849
],
[
849,
63,
272
]
],
[
[
1105,
24,
128
],
[
128,
... | [
[
[
"Trihexyphenidyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Trihexyphenidyl",
"{u} (Compound) resembles {v} (Compound)",
"Cloperastine"
],
[
"Cloperastine",
"{u}... | Trihexyphenidyl (Compound) resembles Cloperastine (Compound) and Cloperastine (Compound) resembles Chlorpheniramine (Compound)
Trihexyphenidyl may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when ta... |
DB01320 | DB06282 | 651 | 516 | [
"DDInter783",
"DDInter1053"
] | Fosphenytoin | Levocetirizine | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repe... | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Moderate | 1 | [
[
[
651,
24,
516
]
],
[
[
651,
63,
1031
],
[
1031,
23,
516
]
],
[
[
651,
63,
701
],
[
701,
24,
516
]
],
[
[
651,
24,
407
],
[
407,
6... | [
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
]
],
[
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophylline"
]... | Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a minor interaction that can limit clinical effects when taken with Levocetirizine
Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Clemastine ... |
DB00304 | DB09043 | 1,657 | 135 | [
"DDInter508",
"DDInter36"
] | Desogestrel | Albiglutide | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on A... | Moderate | 1 | [
[
[
1657,
24,
135
]
],
[
[
1657,
63,
1560
],
[
1560,
24,
135
]
],
[
[
1657,
24,
1144
],
[
1144,
24,
135
]
],
[
[
1657,
1,
35
],
[
35,
... | [
[
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
... | Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide an... |
DB11581 | DB12825 | 1,456 | 1,375 | [
"DDInter1926",
"DDInter1032"
] | Venetoclax | Lefamulin | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lym... | Lefamulin is a pleuromutilin antibiotic used for the treatment of bacterial community-acquired pneumonia. A pleuromotilin is a more recently developed type of antibiotic that is derived from the fungus, Pleurotus mutilus. Lefamulin is available in intravenous and oral preparations and was granted FDA approval in August... | Moderate | 1 | [
[
[
1456,
24,
1375
]
],
[
[
1456,
24,
159
],
[
159,
63,
1375
]
],
[
[
1456,
64,
976
],
[
976,
24,
1375
]
],
[
[
1456,
63,
1101
],
[
1101,
... | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
... | Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin
Venetoclax may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may... |
DB09075 | DB09291 | 498 | 741 | [
"DDInter621",
"DDInter1615"
] | Edoxaban | Rolapitant | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Rolapitant is a potent, highly selective, long-acting Neurokinin-1 (NK-1) receptor antagonist approved for the prevention of delayed chemotherapy-induced nausea and vomiting (CINV) in adults. Delayed-phase CINV typically occurs >24 hours after chemotherapy treatment and is principally mediated by Neurokinin-1 and its l... | Major | 2 | [
[
[
498,
25,
741
]
],
[
[
498,
64,
1671
],
[
1671,
24,
741
]
],
[
[
498,
24,
1496
],
[
1496,
24,
741
]
],
[
[
498,
63,
758
],
[
758,
... | [
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
]
],
[
[
"Edoxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flibanserin"
],
[
"Flibanserin",
"{u} may... | Edoxaban may lead to a major life threatening interaction when taken with Flibanserin and Flibanserin may cause a moderate interaction that could exacerbate diseases when taken with Rolapitant
Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a ... |
DB06292 | DB13007 | 549 | 1,060 | [
"DDInter474",
"DDInter642"
] | Dapagliflozin | Enfortumab vedotin | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protea... | Moderate | 1 | [
[
[
549,
24,
1060
]
],
[
[
549,
24,
913
],
[
913,
23,
1060
]
],
[
[
549,
63,
590
],
[
590,
24,
1060
]
],
[
[
549,
24,
850
],
[
850,
... | [
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
... | Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Acetohe... |
DB01226 | DB01234 | 1,319 | 1,220 | [
"DDInter1235",
"DDInter513"
] | Mivacurium | Dexamethasone | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
1319,
24,
1220
]
],
[
[
1319,
63,
870
],
[
870,
1,
1220
]
],
[
[
1319,
63,
175
],
[
175,
40,
1220
]
],
[
[
1319,
21,
28653
],
[
28653,... | [
[
[
"Mivacurium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Mivacurium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
... | Mivacurium may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Mivacurium may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dex... |
DB09074 | DB14443 | 1,362 | 987 | [
"DDInter1327",
"DDInter1931"
] | Olaparib | Vibrio cholerae CVD 103-HgR strain live antigen | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, ... | Moderate | 1 | [
[
[
1362,
24,
987
]
],
[
[
1362,
24,
1480
],
[
1480,
24,
987
]
],
[
[
1362,
63,
141
],
[
141,
24,
987
]
],
[
[
1362,
64,
1220
],
[
1220,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Olaparib may cause a moderate interaction that could exacerbate diseases when tak... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.